4Tiede DJ, Nishimura RA, Gastineau DA, et al. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc,1998,73(7) :665-680.
5Edmonds LH Jr, Clark RE, Cohn LH, et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations. The American Association for Thoracic Surgery, Ad Hoc Liason Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Ann Thorac Sure, 1996.62(3) : 932-935.
6Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation, 1996, 94(9):2107-2112.
7Butchart EG, Payne N, I.i HH, et al. Better anticoagulation control improves survival after valve replacement. J Thorac Cardlovasc Surg, 2002,123(4):715-723.
8Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement : is an early start advantageous? Ann Thorac Surg, 2001, 72 (1) :44-48.
9Butchart EG, Lewis PA, Bethel JA,et al.Adjusting anticoagulation to prosthesis thrombogenicity and paitent riskfactors [J] .Recommendations for the Medtronic Hall valve. Criculation,1991, 84 (Suppl 5): Ⅲ61
10Milosevic U, Anojcic S.Anticoagulation therapy in cardiac patients with mechanical valve prostheses[J] .Srp Arh Celok Lek, 1990, 118
